GlassScriptPhysician profile
Christopher J Suhar
NPI 1720276751
$6,455.15
in general payments reported to CMS, 2019-2025
33 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $698 · 2021: $1,343 · 2022: $1,168 · 2023: $663 · 2024: $1,023 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,385.36 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $930.08 | 2019-2025 | Lifevest |
| Medtronic, INC. | $621.21 | 2021-2023 | Linq II |
| Amgen INC. | $521.86 | 2019-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $386.97 | 2019-2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $322.84 | 2019-2024 | Andexxa, Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.43 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $260.18 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $210.56 | 2022-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $194.16 | 2019-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $190.28 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $128.86 | 2024-2025 | Amvuttra |
| Boston Scientific Corporation | $125.99 | 2019-2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Irhythm Technologies, INC. | $99.03 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Medtronic Vascular, INC. | $90.58 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $89.85 | 2019-2022 | |
| Baxter Healthcare | $83.42 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $79.24 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $76.98 | 2019-2025 | Eliquis |
| Lantheus Medical Imaging, INC. | $48.91 | 2019-2024 | |
| Edwards Lifesciences Corporation | $31.11 | 2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $28.82 | 2019 | |
| Impulse Dynamics (USA) INC. | $28.73 | 2022 | |
| Astellas Pharma US INC | $28.66 | 2024 | Veozah |
| Kestra Medical Technology Services, INC. | $28.55 | 2024 | Assure Wcd |
| Merck Sharp & Dohme LLC | $24.58 | 2022 | |
| Ionis Pharmaceuticals, INC. | $24.48 | 2025 | Tryngolza |
| Philips North America LLC | $21.77 | 2024 | (Ck4) Mcot |
| Gilead Sciences, INC. | $21.56 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $19.60 | 2024 | Arcalyst |
| Portola Pharmaceuticals, LLC | $19.23 | 2019 | |
| Cvrx, INC. | $19.01 | 2025 | Barostim Neo System |
| Chiesi USA, INC. | $17.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Suhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.